Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

SARS-CoV-2 Vaccine Immune Response on Anti-Complement Therapy, Eculizumab
Autoimmune Neurology
P10 - Poster Session 10 (8:00 AM-9:00 AM)
6-012
Certain Immunomodulatory therapies used to treat autoimmune conditions attenuate immunoglobulin production following SARS CoV-2 vaccination, and may increase susceptibility to COVID-19 infections and/or COVID-19 severity. Here we studied immune response against SARS-CoV-2 vaccine in patients treated with Eculizumab, a disease modifying treatment used for multiple autoimmune conditions including Neuromyelitis Optica Spectrum Disorders (NMOSD).
To investigate immune response against SARS-CoV-2 spike protein in patients treated with anti-complement therapy, Eculizumab.
We searched the Stanford Research Repository (STARR) database and identified 38 patients treated with eculizumab, who were tested for SARS-CoV-2-IgG and SARS-CoV-2 Interferon Gamma Release Assay (IGRA). 7/38 patients were on eculizumab at the time of vaccination against SARS-CoV-2 and testing for vaccine immunity. 
Subjects’ mean age was 49.28±18.7 years (6 females and 1 male) with average duration of eculizumab at the time of first dose of vaccine of 12.7±11.6 months, and the interval between the second dose of vaccine and testing was 7.09±6.2 months. All patients had a positive antibody response to SARS-CoV-2 spike protein IgG (100%). Only 3 patients who had IGRA tested, of which 2 were positive for IGRA (66.66%). Two out of 7 patients (28.6%) had mild lymphopenia at the time of vaccination. Our results contrast with our previously reported cohort of multiple sclerosis patients on anti-CD20 therapy who had 71% (17/24) positive SARS-CoV-2 IGRA but negative for SARS-CoV-2 IgG. These findings are explained by different mechanisms of action for these two medications. 
Based on our findings, eculizumab preserves both B and T cell immunity against SARS-CoV-2 vaccine. The clinical correlation is to be determined. 
Authors/Disclosures
Neda Sattarnezhad, MD (Stanford Univesrity)
PRESENTER
Dr. Sattarnezhad has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD-Serono. Dr. Sattarnezhad has received research support from National MS Society.
Julia Sumera (Stanford Neurology) Miss Sumera has nothing to disclose.
Jamie C. McDonald, MD (Stanford University) Dr. McDonald has nothing to disclose.
Esther H. Nie, PhD (Stanford Healthcare Center for Academic Medicine (CAM)) Dr. Nie has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Medidata, Acorn AI. The institution of Dr. Nie has received research support from Roche/Genentech.
Anna Jessica Tomczak, MSc (Stanford) Miss Tomczak has nothing to disclose.
Yamuna Joseph, MD (Stanford University) Dr. Joseph has nothing to disclose.
Sujatha Kalle, MBBS (Stanford University School of Medicine) Dr. Kalle has nothing to disclose.
Tara Tripathi Sarkar, Other (Stanford University) Miss Sarkar has nothing to disclose.
Lucas Kipp, MD The institution of Dr. Kipp has received research support from Biogen. The institution of Dr. Kipp has received research support from Genentech.
Christopher Lock, MD, MBBS, PhD (Stanford University) Dr. Lock has received personal compensation for serving as an employee of InterX Inc. Dr. Lock has received personal compensation for serving as an employee of Diagnose Early . Dr. Lock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Lock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi . Dr. Lock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono . Dr. Lock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals. Dr. Lock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squib. Dr. Lock has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Lock has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for OGLE, WORM & TRAVIS, PLLP.
Jeffrey E. Dunn, MD, FAAN (Stanford University Medical Center) Dr. Dunn has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Dunn has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Dunn has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Dunn has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme. The institution of Dr. Dunn has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Progentec Diagnostics.
May Han, MD (Stanford University) Dr. Han has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Han has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arena Pharmaceuticals.